News

DaVita HealthCare (DVA) reached $230.72 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.

DaVita stock has delivered a 126.1% return over the past three years, yet valuation checks send mixed signals, with a Discounted Cash Flow (DCF) estimate pointing to a premium while market multiples suggest the shares may still be on the cheap side. DaVita's 126.1% three year return highlights how strongly the stock has rewarded investors who stayed invested over a multi year horizon. Expansion of DaVita's AI driven Integrated Kidney Care platform can support expectations for future cash...

Is DVA a good stock to buy? We came across a bullish thesis on DaVita Inc. on StockCompass’s Substack. In this article, we will summarize the bulls’ thesis on DVA. DaVita Inc.’s share was trading at $228.03 as of July 1st. DVA’s trailing and forward P/E were 21.43 and 15.34 respectively according to Yahoo Finance. DaVita Inc. […]

ADM, CASY, DVA, CVS and BEN top a list of five non-AI S&P 500 stocks that surged more than 30% in 1H 2026 and still show momentum for 2H.

DaVita (NYSE:DVA) is expanding its Integrated Kidney Care platform, adding new capabilities aimed at value-based kidney care delivery. The company is rolling out AI-powered health technologies, including an AI-driven scheduling tool for dialysis care. These updates focus on improving care coordination, patient experience, and operational efficiency across DaVita's network. DaVita enters this phase of product and care model expansion with its stock at $234.91 and a value score of 3. The...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The Pennant Group (PNTG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 2, 2026.

Weschler is responsible for running about 6% of Berkshire’s equity portfolio of more than $300 billion.

DaVita Inc. (NYSE:DVA) is one of the 10 Best Long-Term Stocks to Buy Now According to Warren Buffett. DaVita Inc. (NYSE:DVA) is a healthcare company that caters to the needs of people suffering from kidney ailments. Another long-term Warren Buffet stock pick, Berkshire first disclosed a stake in the firm in the fourth quarter of […]

DVA is advancing kidney care through IKC expansion, CMS CKCC progress and AI-driven dialysis scheduling improvements.

DVA, FIVE, and PBI it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 30, 2026.

Here is how Alignment Healthcare (ALHC) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

In the most recent trading session, DaVita HealthCare (DVA) closed at $217.04, indicating a +1.72% shift from the previous trading day.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Analysts don't like to put "sell" ratings on S&P 500 stocks. So the fact they're willing to do it with some is worth your attention.

LYB, HRB and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 26th, 2026.

The latest trading day saw DaVita HealthCare (DVA) settling at $213.04, representing a +1% change from its previous close.

In recent months, DaVita reported stronger-than-expected first quarter 2026 results, lifted its earnings outlook, and continued to outperform many healthcare peers. An interesting angle is DaVita’s rapid expansion of its value-based Integrated Kidney Care platform, which could reshape how it manages chronic kidney disease patients across the care continuum. Building on this, we’ll explore how the upgraded outlook and Integrated Kidney Care expansion may influence DaVita’s existing...

DVA is expanding kidney care through outpatient, home-centered and value-based programs while investing in AI-enabled scheduling.

HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 24th, 2026.

DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.

Medical stocks Centene, DaVita and BrightSpring are gaining attention as healthcare tailwinds and market optimism support growth.

Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.

DaVita has outperformed other healthcare stocks over the past year, and analysts remain moderately optimistic about its growth prospects.

HRB, DVA and PBI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on June 22nd, 2026.

Murphy, DaVita, Hewlett Packard and Vishay have been highlighted in this Screen of The Week article.

DaVita HealthCare (DVA) closed the most recent trading day at $207.91, moving 1.27% from the previous trading session.

Investors target stocks that have been on a bullish run. Stocks like MUSA, DVA, HPE and VSH are seeing price strength, and the momentum is likely to continue.

DVA is expanding kidney care beyond hospitals with IKC, digital tools and AI to improve coordination, lower costs and support patients.